secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001140361-24-028366
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma
--------------------------------------------------------------------------------

- Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.
- ctDNA molecular response in 42% of PRAME+ patients; trend for longer PFS/OS in molecular responders.
- Combination with pembrolizumab well tolerated; 4/7 evaluable patients achieved disease control including 1 ongoing PR.
- T cell fitness gene signature: high expression associated with 6-month median PFS and 69% DCR vs 2 months/42% for low.
- Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab) enrolling first-line advanced melanoma patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/0001140361-24-028366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/ef20030354_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-028366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer